Telbivudine triphosphate – CAS 152502-95-9
Telbivudine triphosphate – CAS 152502-95-9 is synthesised by Sigut Labs (Prague, Czech Republic).
Purity (LC-MS)
99%+
Package contents
Telbivudine triphosphate Et3NH+ salt
This compound is for research use only. We do not sell to patients.
1 mg | € 800 | Stock | ||
5 mg | € 3500 | Stock | ||
10 mg | € 6500 | Stock | ||
100mM/10μL | € 800 | Stock | ||
10mM/100μL | € 800 | Stock | ||
Do you want custom amount? | Custom amount |
Stock
Stock
Stock
Stock
Stock
Characterisation
Description
Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (European Union) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance. However, HBV signature resistance mutation M204I (a change from methionine to isoleucine at position 204 in the reverse transcriptase domain of the hepatitis B polymerase) or L180M+M204V have been associated with Telbivudine resistance.
Telbivudine is a synthetic thymidine β-L-nucleoside analogue; it is the L-isomer of thymidine. Telbivudine impairs hepatitis B virus (HBV) DNA replication by leading to chain termination. It differs from the natural nucleotide only with respect to the location of the sugar and base moieties, taking on a levorotatory configuration versus a dextrorotatory configuration as do the natural deoxynucleosides
Chemicals are distributed worldwide
Buy Telbivudine triphosphate now, and get your order in 48 hours
- Shipping through DHL in 48 hours
- Sensitive compounds are shipped on dry ice
- All compounds are safely and rigorously packed
Payment
- Payment terms 30 days net
- We are sending the invoice the same day as the shipment
- We are able to modify the invoice for the academic institution, so the order can be paid from grants
References
- Lai, C. L., Leung, N., Teo, E. K., Tong, M., Wong, F., Hann, H. W., … & Telbivudine Phase II Investigator Group. (2005). A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen—positive chronic hepatitis B. Gastroenterology, 129(2), 528-536.
- Lai, C. L., Gane, E., Liaw, Y. F., Hsu, C. W., Thongsawat, S., Wang, Y., … & Brown, N. A. (2007). Telbivudine versus lamivudine in patients with chronic hepatitis B. New England Journal of Medicine, 357(25), 2576-2588.
Similar products
Didn't find the chemical you were looking for?
Contact usWHY CHOOSE
SigutLabs
Your impossible is our starting line